Urinary Catheter Management and Trial Without Catheter (TWOC) Procedure
Patient Preparation and Procedure
- For patients with acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH), alpha blockers should be prescribed prior to TWOC, with a treatment duration of at least 3 days, as recommended by the American Urological Association 1
- The use of alpha blockers, such as alfuzosin and tamsulosin, can improve TWOC success rates from 29-39% (placebo) to 47-60% (with alpha blockers), as reported by the American Urological Association 1
- For post-cesarean patients, the urinary catheter should be removed immediately if strict urine output monitoring is not needed, as suggested by the American College of Obstetricians and Gynecologists 2
- Remove indwelling urinary catheters within 24 hours after admission for acute conditions when possible, according to the Stroke guidelines, and evaluate catheter use daily for surgical patients, removing as early as possible, as suggested by the World Journal of Emergency Surgery guidelines 3, 4
Post-Removal Monitoring and Follow-up
- Patients who pass a successful TWOC for AUR from BPH remain at increased risk for recurrent urinary retention, highlighting the need for long-term follow-up, as noted by the American Urological Association 1
- Long-term data suggests that patients who initially voided successfully with alpha blockers may eventually require surgical intervention, emphasizing the importance of ongoing monitoring and assessment, according to the American Urological Association 1
- Perform post-void residual measurement at follow-up visit, as recommended by the American Urological Association 5
Pharmacological Management
- Alpha blockers, such as alfuzosin and tamsulosin, work by antagonizing alpha1-adrenoreceptors in the prostate and bladder neck, reducing smooth muscle tone, and improving urinary flow, as explained by the American Urological Association 1
- Alfuzosin requires at least 3 days of therapy before attempting a trial without catheter in cases of urinary retention, as recommended by the American Urological Association with a Moderate Recommendation and Evidence Level of Grade B 1
- The American Urological Association recommends alpha blockers, including alfuzosin, as a treatment option for patients with moderate to severe Lower Urinary Tract Symptoms (LUTS)/BPH, with a Moderate Recommendation and Evidence Level of Grade A 1
- Combination therapy with anticholinergics for storage symptoms may be considered if appropriate, although the strength of evidence is not provided, and is supported by the American Urological Association 6
Bladder Training and Catheter Management
- Implement a bladder-training program with scheduled voiding every 2 hours during the day and every 4 hours at night, as recommended by the Stroke guidelines 7
- Intermittent catheterization is recommended if post-void residual urine volume is >100mL, as suggested by the Stroke guidelines 7
- Options for management of failed voiding trials include intermittent catheterization, indwelling catheter, or pharmacological management, with intermittent catheterization recommended every 4-6 hours to prevent bladder filling beyond 500mL, as suggested by the Stroke guidelines 7
- Encourage high fluid intake during the day and decreased fluid intake in the evening, as suggested by the Stroke guidelines 7
- Implementing behavioral techniques such as double voiding, relaxation techniques, and warm sitz baths can help manage symptoms without requiring catheterization, as suggested by the European Association of Urology 1
Surgical Intervention
- Surgical options may be necessary for patients with refractory symptoms, according to the American Urological Association, with long-term data suggesting that 80% of patients who initially voided successfully with alfuzosin eventually required surgical intervention, such as transurethral resection of the prostate (TURP) 1, 6